Education
About Us
Working with TipRanks
Follow Us
Vaxil Bio Ltd (TSE:VXL)
:VXL
VXL Stock Chart & Stats
C$0.13
C$0.00(0.00%)
At close: 4:00 PM EDT
C$0.13
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.13 - C$0.33
Previous CloseN/A
Volume4.43K
Average Volume (3M)1.45K
Market Cap
C$557.76K
Enterprise Value-C$63.46K
Total Cash (Recent Filing)C$347.00K
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.87
Next Earnings
Apr 23, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding3,984,021
10 Day Avg. Volume1,125
30 Day Avg. Volume1,453
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)39.22
Price to Sales (P/S)0.00
P/FCF Ratio-117.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low Leverage / Positive EquityVery low debt and positive equity materially reduce solvency risk and preserve strategic optionality. Over a 2–6 month horizon this balance-sheet strength supports continued R&D investment or partnership negotiations without immediate pressure to take restrictive financing, improving survival odds.
Narrowing LossesA sustained narrowing of operating losses suggests improving cost discipline or R&D efficiency, which strengthens the pathway to eventual break-even. Over months this trend reduces future financing needs and increases the chance that incremental milestones convert to commercial or licensing opportunities.
Improved Cash Burn TrendMeaningful reduction in cash burn extends the company’s runway and lowers immediate dilution risk. Structurally, a sustained improvement gives management more time to advance clinical programs, seek partnerships, or secure non-dilutive funding, improving execution flexibility mid-term.
Bears Say
No Reported RevenueZero reported revenue indicates the business has not validated a commercial model; long-term viability depends on successful development or licensing. Over 2–6 months this maintains high execution and commercialization risk and keeps the company reliant on future clinical or partnership milestones.
Persistent Negative Cash FlowConsistent negative operating and free cash flow means the company must access external capital to operate. Structurally, this creates dilution or debt risk, constrains strategic choices, and can delay or limit development activities absent new funding or a material change in business model.
Eroding Equity / Negative ROEDeclining shareholders' equity and negative ROE reflect accumulated losses and possible dilution, weakening long-term financial resilience. Over months this erodes investor confidence, reduces capital-raising flexibility, and can limit the company's ability to invest in growth or respond to setbacks without costly financing.
Vaxil Bio News
VXL FAQ
What was Vaxil Bio Ltd’s price range in the past 12 months?
Vaxil Bio Ltd lowest stock price was C$0.13 and its highest was C$0.33 in the past 12 months.
What is Vaxil Bio Ltd’s market cap?
Vaxil Bio Ltd’s market cap is C$557.76K.
When is Vaxil Bio Ltd’s upcoming earnings report date?
Vaxil Bio Ltd’s upcoming earnings report date is Apr 23, 2026 which is in 59 days.
How were Vaxil Bio Ltd’s earnings last quarter?
Vaxil Bio Ltd released its earnings results on Nov 27, 2025. The company reported -C$0.007 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.007.
Is Vaxil Bio Ltd overvalued?
According to Wall Street analysts Vaxil Bio Ltd’s price is currently Overvalued.
Does Vaxil Bio Ltd pay dividends?
Vaxil Bio Ltd does not currently pay dividends.
What is Vaxil Bio Ltd’s EPS estimate?
Vaxil Bio Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Vaxil Bio Ltd have?
Vaxil Bio Ltd has 3,984,021 shares outstanding.
What happened to Vaxil Bio Ltd’s price movement after its last earnings report?
Vaxil Bio Ltd reported an EPS of -C$0.007 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -12.5%.
Which hedge fund is a major shareholder of Vaxil Bio Ltd?
Currently, no hedge funds are holding shares in TSE:VXL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Vaxil Bio Ltd
Vaxil Bio Ltd., a biotechnology company, focuses on a novel drug discovery and development platform based on signal peptides for infectious diseases and cancer. The company's lead product is ImMucin that has completed a Phase I/II clinical trial for the treatment of multiple myeloma. It is also developing a tuberculosis vaccine/treatment and a coronavirus (COVID-19) vaccine. The company has a collaboration agreement with The Tel Aviv Sourasky Medical Center for the company's research program to develop a potential peptide vaccine against COVID-19; and cooperative research and development agreement with U.S. Army Medical Research Institute of Infectious Diseases for testing CorVax for its ability to prevent COVID-19 in mice. The company was founded in 2006 and is headquartered in Toronto, Canada.
Technical Analysis
Aptose Biosciences
―
Medicenna Therapeutics Corp
―
BriaCell Therapeutics
―
BioVaxys Technology
―
Defence Therapeutics
―